Effetti cardiovascolari dell'angiotensina-(1-7) nell'invecchiamento
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
A randomized, double blind, placebo-controlled, crossover study will be conducted to determine if acute intravenous angiotensin-(1-7) infusion can reduce cardiovascular sympathetic tone and blood pressure and improve the function of blood vessels in older healthy individuals. This is an outpatient study that requires a screening visit, and if eligible, two study visits separated by at least one week in the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples and endothelial cells collected at baseline and at the end of infusions. Blood pressure, heart rate, and muscle sympathetic nerve activity via microneurography will be measured throughout the study. Each study visit will last approximately 4 hours.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Prima fase 1
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Penn State Milton S. Hershey Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men and women of all races and ethnicities
- Capable of giving informed consent
- Fluent in written and spoken English
- Age 65-80 years
- Body mass index (BMI) between 18.5 and 30 kg/m2
- Normotensive defined as seated blood pressure <130/80 mmHg and without hypertensive medications
- Satisfactory history and physical exam
Exclusion Criteria:
- Age < 65 or > 80 years
- Women who are pregnant, nursing, or taking hormone replacement therapy
- Decisional impairment
- Prisoners
- Current or recent (less than 6 months) recreational drug history or excessive alcohol abuse history (greater than 14 drinks per week)
- Current smokers
- Highly trained athletes
- Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
- Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., cerebral hemorrhage, stroke, transient ischemic attack).
- History or presence of immunological or hematological disorders
- Impaired hepatic function [aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels >2 times upper limit of normal range]
- Impaired renal function (serum creatinine >2.0 mg/dl)
- Anemia
- Taking drugs known to influence sympathetic activity (e.g. serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants).
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month in the 1-month preceding the study)
- Treatment with any investigational drug in the 1-month preceding the study
- Known allergy or contraindication to angiotensin converting enzyme inhibitors or angiotensin receptor blockers, both of which increase endogenous angiotensin-(1-7) levels as part of their mechanism of action
- Inability to give, or withdraw, informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Angiotensin-(1-7)
Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass. |
This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Altri nomi:
|
|
Comparatore placebo: Saline
Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass. |
Saline will be used as the placebo comparator.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Rate
Lasso di tempo: 110 minutes
|
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Incidence
Lasso di tempo: 110 minutes
|
Muscle sympathetic nerve burst incidence will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Muscle Sympathetic Nerve Amplitude
Lasso di tempo: 110 minutes
|
Muscle sympathetic nerve amplitude will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Muscle Sympathetic Nerve Total Activity
Lasso di tempo: 110 minutes
|
Muscle sympathetic nerve total activity will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Brachial Artery Diameter
Lasso di tempo: 110 minutes
|
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Systolic and Diastolic Blood Pressure
Lasso di tempo: 110 minutes
|
Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Heart Rate
Lasso di tempo: 110 minutes
|
Heart rate will be measured continuously by electrocardiogram during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Heart Rate Variability
Lasso di tempo: 110 minutes
|
Heart rate variability will be calculated from the continuous electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Plasma Catecholamines
Lasso di tempo: 110 minutes
|
Circulating catecholamine levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Angiotensin II
Lasso di tempo: 110 minutes
|
Plasma angiotensin II levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Angiotensin-(1-7)
Lasso di tempo: 110 minutes
|
Plasma angiotensin-(1-7) levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Renin Activity
Lasso di tempo: 110 minutes
|
Plasma renin activity will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
|
Change in Aldosterone
Lasso di tempo: 110 minutes
|
Plasma or serum aldosterone levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
110 minutes
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Amy Arnold, PhD, Pennsylvania State University College of Medicine
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Prodotti chimici organici
- Preparati farmaceutici
- Acidi grassi
- Lipidi
- Acidi, aciclici
- Acidi carbossilici
- Prodotti chimici inorganici
- Composti di cloro
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Acidi grassi, volatile
- Composti di sodio
- Cloruri
- Acido cloridrico
- Soluzione salina
- Cloruro di sodio
- Acetate
- Angiotensina I (1-7)
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- STUDY 17401
- K99HL159272 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .